All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IPR-179
Therapeutic Area: Neurology Product Name: ACT-03
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2021
Details:
The study results show that the ACT-03, when administered in animal models over one week, can slow the progression of the disease by reducing the severity and number of spontaneous seizures (up to seven weeks after initial drug administration).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Baupost Group
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 25, 2021
Details:
The new capital, alongside company's recently announced collaboration with Eisai supports lead small molecule programs targeting amyloid-β and α-synuclein, with first clinical candidate for amyloid-β in Q1 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: LifeArc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 18, 2021
Details:
The collaboration focuses on the discovery of novel selective small molecular modulators of a specific two-pore potassium ion target, identified as likely to be involved in neurological pathogenesis, and has now progressed to the hit-to-lead optimization phase.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: GlaxoSmithKline
Deal Size: $161.5 million Upfront Cash: $7.0 million
Deal Type: Collaboration December 21, 2020
Details:
The deal will leverage Icagen’s expertise in small molecule therapeutics targeting transmembrane proteins, utilising the company’s discovery technology to identify and develop inhibitors of a ‘specific genetically-validated molecular target’ relevant to neurological diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): C9orf2 -ALS
Therapeutic Area: Neurology Product Name: C9orf2 -ALS
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vida Ventures LLC
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 14, 2020
Details:
Funding supports pre-clinical and clinical development of proprietary RNA-targeting systems delivered via gene therapy for treating genetic diseases such as Huntington’s disease, myotonic dystrophy type 1, genetic ALS, and retinal disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Third Rock Ventures
Deal Size: $81.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 10, 2020
Details:
The Series A will support Faze’s preclinical research in two initial therapeutic focus areas – ALS and myotonic dystrophy type 1 (DM1) – as well as research to explore condensate biology in other disease areas.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV-mediated gene therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: UCB Pharma S.A.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 12, 2020
Details:
New collaboration with Lacerta Therapeutics underlines UCB’s strategic focus in gene therapy to fulfil its Patient Value Ambition. New R&D collaboration with Lacerta Therapeutics provides access to a novel gene therapy program and proprietary AAV capsids.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Bristol-Myers Squibb
Deal Size: $2,100.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration October 28, 2020
Details:
Insitro will apply its proprietary platform, the insitro Human (ISH) platform, to create induced pluripotent stem cell (iPSC) derived disease models for ALS and FTD. BMS will be responsible for clinical development and regulatory submissions and commercialization activities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Ther
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
